INmune Bio Inc. Announces Approval Of Clinical Trial Application By The U.K. Medicines And Healthcare Products Regulatory Agency For Phase 2 Clinical Trial In Alzheimer's Disease
Portfolio Pulse from Happy Mohamed
INmune Bio, Inc. (NASDAQ:INMB) has received approval from the U.K. Medicines and Healthcare Products Regulatory Agency to expand its ongoing Phase 2 trial of XPro in patients with early Alzheimer's disease to the U.K. The trial is also enrolling patients in Australia and Canada. In a prior Phase I trial, INmune Bio met all primary and secondary endpoints, with patients showing significant reductions in neuroinflammation and improvements in axonal integrity and synaptic function.
September 05, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
INmune Bio's approval to expand its Phase 2 trial of XPro to the U.K. could potentially accelerate patient enrollment and advance the development of the drug. The successful results from the Phase I trial also bode well for the company.
The approval to expand the trial to the U.K. could potentially speed up patient enrollment and the development of XPro. The successful results from the Phase I trial also indicate that the drug could be effective in treating early Alzheimer's disease, which could have a positive impact on INmune Bio's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100